Cholesterol as a causative factor in Alzheimer's disease: A debatable hypothesis

Journal of Neurochemistry

Volumn 129, Issue 4, 2014, Pages 559-572

  Wood, W Gibson ^a   Li, Ling ^b   Müller, Walter E ^c   Eckert, Gunter P ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; amyloid beta protein; apolipoprotein E; cholesterol; isoprenoids; statins

Indexed keywords

24 HYDROXYCHOLESTEROL; AMYLOID BETA PROTEIN; CHOLESTEROL DERIVATIVE; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL HOMEOSTASIS; CHOLESTEROL SYNTHESIS; DISEASE COURSE; HOMEOSTASIS; HUMAN; LIPID BRAIN LEVEL; LIPID RAFT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PRENYLATION; REVIEW; RISK FACTOR; SYNAPTIC MEMBRANE;

ALZHEIMER'S DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; ISOPRENOIDS; STATINS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; ASTROCYTES; CELL MEMBRANE; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL, DIETARY; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYCHOLESTEROLS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MICE; MODELS, BIOLOGICAL; NEURONS; POLYISOPRENYL PHOSPHATES; RABBITS; SESQUITERPENES;

EID: 84899490048     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12637     Document Type: Review

References (162)

1. Avdulov N. A., Chochina S. V., Igbavboa U., Vassiliev A. V., and, Wood W. G., (1997) Lipid binding to amyloid β-peptide: Preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J. Neurochem. 69, 1746-1752. (Pubitemid 27406976)
2. Barrett P. J., Song Y., Van Horn W. D., Hustedt E. J., Schafer J. M., Hadziselimovic A., Beel A. J., and, Sanders C. R., (2012) The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336, 1168-1171.
3. Borroni V., and, Barrantes F. J., (2011) Cholesterol modulates the rate and mechanism of acetylcholine receptor internalization. J. Biol. Chem. 286, 17122-17132.
4. Brown M. S., and, Goldstein J. L., (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34-47. (Pubitemid 16037973)
5. Burns M. P., and, Rebeck G. W., (2010) Intracellular cholesterol homeostasis and amyloid precursor protein processing. Biochim. Biophys. Acta 1801, 853-859.
6. Burns M. P., Igbavboa U., Wood W. G., and, Duff K., (2006) Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice. NeuroMol. Med. 8, 319-328.
7. Castellano J. M., Kim J., Stewart F. R., et al,. (2011) Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med. 3, 89ra57.
8. Cedazo-Mínguez A., Hamker U., Meske V., Veh R. W., Hellweg R., Jacobi C., Albert F., Cowburn R. F., and, Ohm T. G., (2001) Regulation of apolipoprotein E secretion in rat primary hippocampal astrocyte cultures. Neuroscience 105, 651-661. (Pubitemid 32769829)
9. Christensen D. J., Ohkubo N., Oddo J., Van Kanegan M. J., Neil J. E., Li F. Q., Colton C. A., and, Vitek M. P., (2011) Apolipoprotein E and peptide mimetics mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J. Immunol. 186, 2535-2542.
10. Cole S. L., and, Vassar R., (2006) Isoprenoids and Alzheimer's disease: a complex relationship. Neurobiol. Dis. 22, 209-222.
11. 125I]azido-cholesterol. Biochim. Biophys. Acta 1414, 65-74. (Pubitemid 28511040)
12. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Jr, Small G. W., Roses A. D., Haines J. L., and, Pericak-Vance M. A., (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923. (Pubitemid 23275809)
13. Corder E. H., Saunders A. M., Risch N. J., et al,. (1994) Protective effects of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7, 180-184. (Pubitemid 24174658)
14. Daviglus M. L., Bell C. C., Berrettini W., et al,. (2010) National Institues of Health state-of-the-science conference statement: preventing Alzheimer's disease and cognitive decline. NIH Consens. State Sci. Statements 27, 1-30.
15. Dekroon R. M., and, Armati P. J., (2001) Synthesis and processing of apolipoprotein E in human brain cultures. Glia 33, 298-305. (Pubitemid 32285746)
16. Désiré L., Bourdin J., Loiseau N., et al,. (2005) Rac1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases abeta production in vitro and in vivo. J. Biol. Chem. 280, 37516-37525. (Pubitemid 41642360)
17. Di Scala C., Yahi N., Lelièvre C., Garmy N., Chahinian H., and, Fantini J., (2013) Biochemical identification of a linear cholesterol-binding domain within Alzheimer's β amyloid peptide. ACS Chem. Neurosci. 20, 509-517.
18. Dietschy J. M., and, Turley S. D., (2004) Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45, 1375-1397. (Pubitemid 39022664)
19. Downward J., (2003) Targeting RAS signalling pathways in cancer therapy. Nat. Cancer Rev. 3, 11-22. (Pubitemid 37328883)
20. Eckert G. P., Cairns N. J., Maras A., Gattaz W. F., and, Müller W. E., (2000) Cholesterol modulates the membrane disordering effects of β-amyloid peptides in the hippocampus: Specific changes in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 11, 181-186. (Pubitemid 30416021)
21. Eckert G. P., Hooff G. P., Strandjord D. M., Igbavboa U., Volmer D. A., Müller W. E., and, Wood W. G., (2009) Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol. Dis. 35, 251-257.
22. Eckert G. P., Wood W. G., and, Müller W. E., (2010) Lipid membranes and beta-amyloid: a harmful connection. Curr. Protein Pept. Sci. 11, 319-325.
23. Eckert G. P., Reik C., and, Muller W. E., (2013) Simvastatin alters membrane cholesterol distribution and beta-amyloid levels in brains of APP751SL mice. Pharmazie 68, 590-594.
24. Erickson M. A., and, Banks W. A., (2013) Blood-brain barrier dysfunction as cause and consequence of Alzheimer's disease. J. Cereb. Blood Flow Metab. 33, 1-14.
25. Farrer L. A., Cupples L. A., Haines J. L., Hyman B. T., Kukull W. A., Mayeux R., Myers R. H., Pericak-Vance M. A., Risch N., and, van Duijn C. M., (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 278, 1349-1356. (Pubitemid 27449696)
26. Gamba P., Testa G., Sottero B., Gargiulo S., Poli G., and, Leonarduzzi G., (2012) The link between altered cholesterol metabolism and Alzheimer's disease. Ann. N. Y. Acad. Sci. 1259, 54-64.
27. Gärtner U., Holzer M., Heumann R., and, Arendt T., (1995) Induction of p21ras in Alzheimer pathology. NeuroReport 10, 1441-1444.
28. Gärtner U., Holzer M., and, Arendt T., (1999) Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration. Neuroscience 91, 1-5. (Pubitemid 29170442)
29. Go A. S., Mozaffarian D., Roger V. L., et al,. and on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2013) Heart disease and stroke statistics-2013 Update: a report from the American Heart Association. Circulation 127, e6-e245.
30. Gong J. S., Kobayashi M., Hayashi H., Zou K., Sawamura N., Fujita S. C., Yanagisawa K., and, Michikawa M., (2002) Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human apoE3 and apoE4 knock-in mice. J. Biol. Chem. 277, 29919-29926.
31. Halford R. W., and, Russel D. W., (2009) Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer's disease, but does extend lifespan. Proc. Natl Acad. Sci. USA 106, 3502-3506.
32. 2-adrenergic receptor. Structure 16, 897-905. (Pubitemid 351778384)
33. Hayashi H., Igbavboa U., Hamanaka H., Kobayashi M., Fujita S. C., Wood W. G., and, Yanagisawa K., (2002) Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. NeuroReport 13, 383-386. (Pubitemid 34293174)
34. Head B. P., Patel H. H., and, Insel P. A., (2014) Interaction of membrane/lipid rafts with the cytoskelton: impact on signaling and function: membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling. Biochim. Biophys. Acta, 1838, 532-545.
35. Hebert L. E., Weuve J., Scherr P. A., and, Evans D. A., (2013) Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 80, 1778-1783.
36. Heino S., Lusa S., Somerharju P., Ehnholm C., Olkkonen V. M., and, Ikonen E., (2000) Dissecting the role of the Golgi complex and lipid rafts in biosynthetic transport of cholesterol to the cell surface. Proc. Natl Acad. Sci. USA 97, 8375-8380. (Pubitemid 30639680)
37. Herman G. E., and, Kratz L., (2012) Disorders of sterol synthesis: beyond Smith-Lemli-Opitz syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 160, 301-321.
38. Heverin M., Bogdanovic N., Lutjohann D., Bayer T. A., Pikuleva I., Bretillon L., Diczfalusy U., Winblad B., and, Björkhem I., (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J. Lipid Res. 45, 186-193. (Pubitemid 38180529)
39. Hirsch-Reinshagen V., and, Wellington C. L., (2007) Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease. Curr. Opin. Lipidol. 18, 325-332. (Pubitemid 46743058)
40. Holtzman D. M., Bales K. R., Tenkova T., Sartorius L., Paul S. M., Bales K., Ashe K. H., Irizarry M. C., and, Hyman B. T., (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 97, 2892-2897. (Pubitemid 30159268)
41. Holtzman D. M., Herz J., and, Bu G., (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 3, a006312.
42. Hooff G. P., Wood W. G., Müller W. E., and, Eckert G. P., (2010) Isopernoids, small GTPases and Alzheimer's disease. Biochim. Biophys. Acta 1801, 896-905.
43. Hooff G. P., Wood W. G., Hyun K. J., Igbavboa U., Ong W. Y., Müller W. E., and, Eckert G. P., (2012) Brain isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate are increased in aged mice. Mol. Neurobiol. 46, 179-185.
44. Horton J. D., Goldstein J. L., and, Brown M. S., (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131. (Pubitemid 34496588)
45. Hu J., LaDu M. J., and, Van Eldik L. J., (1998) Apolipoprotein E attenuates beta-amyloid-induced astrocyte activation. J. Neurochem. 71, 1626-1634. (Pubitemid 28443035)
46. Huesa G., Baltrons M. A., Gõmez-Ramos P., Morán A., García A., Hidalgo J., Francés S., Santpere G., and, Galea E., (2010) Altered distribution of RhoA in Alzheimer's disease and abetaPP overexpressing mice. J. Alzheimers Dis. 19, 37-56.
47. Igbavboa U., Avdulov N. A., Schroeder F., and, Wood W. G., (1996) Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. J. Neurochem. 66, 1717-1725. (Pubitemid 26090575)
48. Igbavboa U., Avdulov N. A., Chochina S. V., and, Wood W. G., (1997) Transbilayer distribution of cholesterol is modified in brain synaptic plasma membranes of knockout mice deficient in the low density lipoprotein receptor, apolipoprotein E, or both proteins. J. Neurochem. 69, 1661-1667. (Pubitemid 27406967)
49. 1-42. J. Biol. Chem. 278, 17150-17157. (Pubitemid 36799593)
50. Igbavboa U., Eckert G. P., Malo T. M., et al,. (2005) Murine synaptosomal lipid raft protein and lipid composition are altered by expression of human apoE3 and 4 and by increasing age. J. Neurol. Sci. 229-230, 225-232. (Pubitemid 40341587)
51. Igbavboa U., Johnson-Anuna L. N., Rossello X., Butterick T. A., Sun G. Y., and, Wood W. G., (2006) Amyloid beta-protein 1-42 increases cAMP and apolipoprotein E levels which are inhibited by β1 and β2-adrenergic receptor antagonists in mouse primary astrocytes. Neuroscience 142, 655-660. (Pubitemid 44508712)
52. Igbavboa U., Sun G. Y., Weisman G. A., and, Wood W. G., (2009) Amyloid β-protein stimulates trafficking of cholesterol and caveolin-1 from the plasma membrane to the Golgi complex in mouse primary astrocytes. Neuroscience 162, 328-338.
53. Jarvik G. P., Wijsman E. M., Kukull W. A., Schellenberg G. D., Yu C., and, Larson E. B., (1995) Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45, 1092-1096.
54. Junker V., Becker A., Hühne R., Zembatov M., Ravati A., Culmsee C., and, Krieglstein J., (2002) Stimulation of β-adrenoceptors activates astrocytes and provides neuroprotection. Eur. J. Pharmacol. 446, 25-36. (Pubitemid 34722554)
55. Kabara J. J., (1973) A critical review of brain cholesterol metabolism. Prog. Brain Res. 40, 363-382.
56. Karasinska J. M., and, Hayden M. R., (2011) Cholesterol metabolism in Huntington disease. Nat. Rev. Neurol. 7, 561-572.
57. Kim J., Basak J. M., and, Holtzman D. M., (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63, 287-303.
58. Kirsch C., Eckert G. P., Koudinov A. R., and, Müller W. E., (2003a) Brain cholesterol, statins and Alzheimer's Disease. Pharmacopsychiatry 36, S113-S119. (Pubitemid 37346641)
59. Kirsch C., Eckert G. P., and, Müller W. E., (2003b) Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem. Pharmacol. 65, 843-856. (Pubitemid 36293701)
60. Kivipelto M., Helkala E.-L., Laakso M. P., Hänninen T., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., and, Nissien A., (2001) Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal population based study. BMJ 322, 1447-1451. (Pubitemid 32575406)
61. Knittweis J. W., and, McMullen W. A., (2000) The effect of apoE on dementia is not through atherosclerosis: the rotterdam study: to the editor. Neurology 54, 2356-2358. (Pubitemid 30416303)
62. Korade Z., and, Kenworthy A. K., (2008) Lipid rafts, cholesterol, and the brain. Neuropharmacology 55, 1265-1273.
63. Kotti T. J., Ramirez D. M., Pfeiffer B. E., Huber K. M., and, Russell D. W., (2006) Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc. Natl Acad. Sci. USA 103, 3869-3874. (Pubitemid 43376647)
64. Kotti T. J., Head D. D., McKenna C. E., and, Russell D. W., (2008) Biphasic requirement for geranylgeraniol in hippocampal long-term potentiation. Proc. Natl Acad. Sci. USA 105, 11394-11399.
65. Koudinov A. R., Koudinova N. V., and, Berezov T. T., (1996) Alzheimer's peptides Aβ1-40 and Aβ1-28 inhibit the plasma cholesterol esterification rate. Biochem. Mol. Biol. Int. 38, 747-752. (Pubitemid 26258305)
66. Koudinova N. V., Berezov T. T., and, Koudinov A. R., (1996) Multiple inhibitory effects of Alzheimer's peptide Aβ1-40 on lipid biosynthesis in cultured human HepG2 cells. FEBS Lett. 395, 204-206. (Pubitemid 26356186)
67. van de Kraats C., Killestein J., Popescu V., Rijkers E., Vrenken H., Lütjohann D., Barkhof F., Polman C., and, Teunissen C,. (2014) Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. Mult. Scler, 20, 412-417.
68. Kuo Y.-M., Emmerling M. R., Bisgaier C. L., Essenburg A. D., Lampert H. C., Drumm D., and, Roher A. E., (1998) Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1-42 levels. Biochem. Biophys. Res. Commun. 252, 711-715. (Pubitemid 28556841)
69. LaDu M. J., Shah J. A., Reardon C. A., Getz G. S., Bu G., Hu J., Guo L., and, Van Eldik L. J., (2000) Apolipoprotein E receptors mediate the effects of β-amyloid on astrocyte cultures. J. Biol. Chem. 275, 33974-33980.
70. LaDu M. J., Shah J. A., Reardon C. A., Getz G. S., Bu G., Hu J., Guo L., and, Van Eldik L. J., (2001) Apolipoprotein E and apolipoprotein E receptors modulate Aβ-induced glial neuroinflammatory responses. Neurochem. Int. 39, 427-434. (Pubitemid 32907407)
71. de Lau M. L., Koudstaal P. J., Hofman A., and, Breteler M. M. B., (2006) Serum cholesterol levels and the risk of Parkinson's disease. Am. J. Epidemiol. 164, 998-1002. (Pubitemid 44729842)
72. Laureys G., Clinckers R., Gerlo S., Spooren A., Wilczak N., Kooijman R., Smolders I., Michhhhotte Y., and, De Keyser J., (2010) Astrocytic beta(2)-adrenergic receptors: from physiology to pathology. Prog. Neurobiol. 91, 189-199.
73. Lazar A. N., Bich C., Panchal M., et al,. (2013) Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patients. Acta Neuropathol. 125, 133-144.
74. Lee A. G., (2011) Biological membranes: the importance of molecular detail. Trends Biochem. Sci. 36, 493-500.
75. Leoni V., Long J. D., Mills J. A., Di Donato S., Paulsen J. S., and the members of the PREDICT-HD study group (2013) Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression. Neurobiol. Dis. 55, 37-43.
76. Li G., Shofer J. B., Kukull W. A., et al,. (2005) Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 65, 1045-1050. (Pubitemid 41429629)
77. Li F. Q., Fowler K. A., Neil J. E., Colton C. A., and, Vitek M. P., (2010) An apolipoprotein E-mimetic stimulates axonal regeneration and remyelination after peripheral nerve injury. J. Pharmacol. Exp. Ther. 334, 106-115.
78. Li L., Zhang W., Cheng S., and, Cao D., (2012) Isoprenoids and related pharmacological interventions: Potential application in Alzheimer's disease. Mol. Neurobiol. 46, 64-77.
79. Liao J. K., and, Laufs U., (2004) Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45, 89-118.
80. Liguori N., Nerenberg P. S., and, Head-Gordon T., (2013) Embedding Aβ42 in heterogeneous membranes depends on cholesterol asymmetries. Biophys. J. 105, 899-910.
81. Linseman D. A., and, Loucks F. A., (2008) Diverse roles of Rho family GTPases in neuronal development, survival, and death. Front. Biosci. 13, 657-676. (Pubitemid 351599775)
82. Liu Y., Peterson D. A., and, Schubert D., (1998) Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc. Natl Acad. Sci. USA 95, 13266-13271. (Pubitemid 28509560)
83. Liu C. C., Kanekiyo T., Xu H., and, Bu G., (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106-118.
84. Lund E. G., Xie C., Kotti T., Turley S. D., Dietschy J. M., and, Russell D. W., (2003) Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem. 278, 22980-22988. (Pubitemid 36830363)
85. Lütjohann D., and, von Bergmann K., (2003) 24S-hydroxycholesterol: a marker of brain cholesterol metabolism. Pharmacopsychiatry 36, S102-S106. (Pubitemid 37346639)
86. Ma Q.-L., Yang F., Calon F., Ubeda O. J., Hansen J. E., Weisbart R. H., Beech W., Frautschy S. A., and, Cole G. M., (2008) p21-activated Kinase-aberrant Activation and Translocation in Alzheimer Disease Pathogenesis. J. Biol. Chem. 283, 14132-14143.
87. Mahley R. W., (1988) Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240, 622-630.
88. Mans R. A., McMahon L. L., and, Li L., (2012) Simvastatin-mediated enhancement of lonf-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation. Neuroscience 202, 1-9.
89. Martin V., Fabelo N., Santpere G., Puig B., Marin R., Ferrer I., and, Díaz M., (2010) Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J. Alzheimers Dis. 19, 489-502.
90. Mason R. P., Shoemaker W. J., Shajenko L., Chambers T. E., and, Herbette L. G., (1992) Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol. Aging 13, 413-419.
91. Mason R. P., Estermyer J. D., Kelly J. F., and, Mason P. E., (1996) Alzheimer's disease amyloid beta peptide 25-35 is localized in the membrane hydrocarbon core: X-ray diffraction analysis. Biochem. Biophys. Res. Commun. 222, 78-82. (Pubitemid 26152208)
92. Matsuo M., Togawa M., Hirabaru K., Mochinaga S., Narita A., Adachi M., Egashira M., Irie T., and, Ohno K., (2013) Effects of cyclodextrin in two patients with Niemann-Pick Type C disease. Mol. Genet. Metab. 108, 76-81.
93. Maulik M., Westaway D., Jhamandas J. H., and, Kar S., (2013) Role of cholesterol in APP metabolism and its significance in Alzheimer's disease pathogenesis. Mol. Neurobiol. 47, 37-63.
94. McGuinness B., O'Hare J., Craig D., Bullock R., Malouf R., and, Passmore P., (2013) Cochrane review on 'Statins for the treatment of dementia'. Int. J. Geriatr. Psychiatry 28, 119-126.
95. McTaggart S. J., (2006) Isoprenylated proteins. Cell. Mol. Life Sci. 63, 255-267. (Pubitemid 43202309)
96. Mendez A. J., (1995) Monensin and brefeldin A inhibit high density lipoprotein-mediated cholesterol efflux from cholesterol-enriched cells: Implications for intracellular cholesterol transport. J. Biol. Chem. 270, 5891-5900.
97. 1-42 stimulates actin polymerization in hippocampal neurons through Rac1 and CDC42 Rho GTPases. J. Cell Sci. 120, 279-288.
98. Michikawa M., Fan Q.-W., Isobe I., and, Yanagisawa K., (2000) Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J. Neurochem. 74, 1008-1016. (Pubitemid 30104296)
99. Michikawa M., Gong J.-S., Fan Q.-W., Sawamura N., and, Yanagisawa K., (2001) A novel action of Alzheimer's amyloid β-protein (Aβ): Oligomeric Aβ promotes lipid release. J. Neurosci. 18, 7226-7235. (Pubitemid 32846970)
100. Mo H., Yeganehjoo H., Shah A., Mo W. K., Soelaiman I. N., and, Shen C.-L., (2012) Mevalonate-suppressive dietary isoprenoids for bone health. J. Nutr. Biochem. 23, 1543-1551.
101. Mohamed A., Saavedra L., Di Pardo A., Sipione S., and, Posse de Chaves E., (2012) β-amyloid inhibits protein prenylation and induces cholesterol sequestration by impairing SREBP-2 cleavage. J. Neurosci. 32, 6490-6500.
102. Nicholson A. M., and, Ferreira A., (2009) Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calplain activation and tau toxicity. J. Neurosci. 29, 4640-4651.
103. Nixon R. A., (2004) Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up. Am. J. Pathol. 164, 757-761. (Pubitemid 38235457)
104. North P., and, Fleischer S., (1983) Alteration of synaptic membrane cholesterol/phospholipid ratio using a lipid transfer protein. J. Biol. Chem. 258 (2), 1242-1253. (Pubitemid 13139368)
105. Oh D., Han S., Seo J., et al,. (2010) Regulation of synaptic Rac1 activity, long-term potentiation maintenance, and learning and memory by BCR and ABR Rac GTPase-activating proteins. J. Neurosci. 30, 14134-14144.
106. Ong W. Y., Tanaka K., Dawe G. S., Ittner L. M., and, Farooqui A. A., (2013) Slow excitotoxicity in Alzheimer's disease. J. Alzheimers Dis. 35, 643-668.
107. Papassotiropoulos A., Lutjohann D., Bagli M., Locatelli S., Jessen F., Buschfort R., Ptok U., Bjorkhem I., von Bergmann K., and, Heun R., (2002) 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36, 27-32. (Pubitemid 34037845)
108. Pappolla M. A., Bryant-Thomas T., Herbert D., et al,. (2003) Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61, 199-205. (Pubitemid 36875301)
109. Parton R. G., and, del Pozo M. A., (2013) Caveolae as plasma membranes sensors, protectors and organizers. Nat. Rev. Mol. Cell Biol. 14, 98-112.
110. Passarelli M. K., and, Winograd N., (2013) Lipid imaging with time-of-flight secondary ion mass spectrometry (ToF-SIMS). Biochim. Biophys. Acta 1811, 976-990.
111. Pierrot N., Tyteca D., D'auria L., et al,. (2013) Amyloid precursor protein controls cholesterol turnover needed for neuronal activity. EMBO Mol. Med. 5, 608-625.
112. Pilpel Y., and, Segal M., (2004) Activation of PKC induces rapid morphol-ogical plasticity in dendrites of hippocampal neurons via Rac and Rho-dependent mechanisms. Eur. J. Neurosci. 19, 3151-3164. (Pubitemid 38859532)
113. Poirier J., (1994) Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 17, 525-530.
114. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., and, Gauthier S., (1993) Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342, 697-699. (Pubitemid 23279761)
115. Popp J., Lewczuk P., Kolsch H., Meichsner S., Kornhuber J., Jessen F., and, Lütjohann D., (2012) Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. J. Neurochem. 123, 310-316.
116. Popp J., Meichsner S., Kölsch H., Lewczuk P., Maier W., Kornhuber J., Jessen F., and, Lütjohann D., (2013) Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. Biochem. Pharmacol. 86, 37-42.
117. Posse de Chaves E. I., (2012) Reciprocal regulation of cholesterol and beta amyloid at the subcellular level in Alzheimer's disease. Can. J. Physiol. Pharmacol. 90, 753-764.
118. Ramakers G. J., (2002) Rho proteins, mental retardation and the cellular basis of cognition. Trends Neurosci. 25, 191-199. (Pubitemid 34615536)
119. Ramirez D. M. O., Andersson S., and, Russel D. W., (2008) Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain. J. Comp. Neurol. 507, 1676-1693. (Pubitemid 351468217)
120. Rapp A., Gmeiner B., and, Huttinger M., (2006) Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. Biochimie 88, 473-483. (Pubitemid 43867898)
121. Rebeck G. W., Kindy M., and, LaDu M. J., (2002) Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J. Alzheimers Dis. 4, 145-154. (Pubitemid 35006046)
122. Reddy S., and, Comai L., (2012) Lamin A, farnesylation and aging. Exp. Cell Res. 318, 1-7.
123. Romas S. N., Tang M. X., Berglund L., and, Mayeux R., (1999) ApoE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 53, 517-521. (Pubitemid 29382044)
124. Roskoski R., (2003) Protein prenylation: a pivotal posttranslational process. Biochem. Biophys. Res. Commun. 303, 1-7.
125. Rossello X. S., Igbavboa U., Weisman G. A., Sun G. Y., and, Wood W. G., (2012) AP-2β regulates amyloid beta-protein stimulation of apolipprotein E transcription in astrocytes. Brain Res. 1444, 87-95.
126. Schroeder F., Gallegos A. M., Atshaves B. P., et al,. (2001) Recent advances in membrane microdomains: Rafts, caveolae, and intracellular cholesterol trafficking. Exp. Biol. Med. 226, 873-890.
127. Schroeder F., Huang H., McIntosh A. L., Atshaves B. P., and, Kier A. B., (2010) Caveolin, sterol carrier protein-2, membrane cholesterol-rich microdomains and intracellular cholesterol trafficking. Subcell. Biochem. 51, 279-318.
128. Sekino Y., Kojima N., and, Shirao T., (2007) Role of actin cytoskelton in dendritic spine morphogenesis. Neurochem. Int. 51, 92-104. (Pubitemid 47176704)
129. Solomon A., Kivipelto M., Wolozin B., Zhou J., and, Whitmer R. A., (2009a) Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement. Geriatr. Cogn. Disord. 28, 75-80.
130. Solomon A., Leoni V., Kivipelto M., et al,. (2009b) Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease. Neurosci. Lett. 462, 89-93.
131. Sonnino S., and, Prinetti A., (2013) Membrane domains and the "lipid raft" concept. Curr. Med. Chem. 20, 4-21.
132. Sparks D. L., (1997) Coronary artery disease, hypertension, apoE, and cholesterol: a link to Alzheimer's disease? Ann. N. Y. Acad. Sci. 826, 128-146.
133. Sparks D. L., Hunsaker J. C., III, Scheff S. W., Kryscio R. J., Henson J. L., and, Markesbery W. R., (1990) Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol. Aging 11, 601-607.
134. Sparks D. L., Scheff S. W., Hunsaker J. C., III, Liu H., Landers T., and, Gross D. R., (1994) Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 88-94.
135. Stewart R., White L. R., Xue Q.-L., and, Launer L. J., (2007) Twenty-six-year change in total cholesterol levels and incident dementia. Arch. Neurol. 64, 103-107. (Pubitemid 46072431)
136. Strittmatter W. J., and, Roses A. D., (1996) Apolipoprotein E and Alzheimer's disease. Annu. Rev. Neurosci. 19, 53-77. (Pubitemid 26080822)
137. Tan Z. S., Seshadri S., Beiser A., Wilson P. W. F., Kiel D. P., Tocco M., D'Agostino R. B., and, Wolf P. A., (2003) Plasma total cholesterol level as a risk factor for Alzheimer disease. Arch. Intern. Med. 163, 1053-1057. (Pubitemid 36548931)
138. Tolias K. F., Duman J. G., and, Um K., (2011) Control of synapse development and plasticity by Rho GTPase regulatory proteins. Prog. Neurobiol. 94, 133-148.
139. Vance J. E., Hayashi H., and, Karten B., (2005) Cholesterol homeostasis in neurons and glial cells. Semin. Cell Dev. Biol. 16, 193-212. (Pubitemid 40432121)
140. Verghese P. B., Castellano J. M., and, Holtzman D. M., (2011) Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 10, 241-252.
141. Verghese P. B., Castellano J. M., Garai K., Wang Y., Jiang H., Shah A., Bu G., Frieden C., and, Holtzman D. M., (2013) ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc. Natl Acad. Sci. USA 110, 1807-1816.
142. Wang H., Durham L., Dawson H., Song P., Warner D. S., Sullivan P. M., Vitek M. P., and, Laskowitz D. T., (2007) An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction. Neuroscience 144, 1324-1333. (Pubitemid 46123809)
143. Wang P.-L., Niidome T., Akaike A., Kihara T., and, Sugimoto H., (2009) Rac1 inhibition negatively regulates transcriptional activity of the amyloid precursor protein gene. J. Neurosci. Res. 87, 2105-2114.
144. Wang D., Govindaiah G., Liu R., De Arcangelis V., Cox C. L., and, Xiang Y. K., (2010) Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. FASEB J. 24, 3511-3521.
145. Weber M. S., Prod'homme T., Steinman L., and, Zamvil S. S., (2005) Drug Insight: using statins to treat neuroinflammatory disease. Nat. Clin. Pract. Neurol. 1, 106-112.
146. Whitmer R. A., Sidney S., Selby J., Johnston C., and, Yaffe K., (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64, 277-281.
147. Wiemer A. J., Hohl R. J., and, Wiemer D. F., (2009) The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anticancer Agents Med. Chem. 9, 526-542.
148. Williamson R., and, Sutherland C., (2011) Neuronal membranes are key to the pathogenesis of Alzheimer's disease: the role of both raft and non-raft membrane domains. Curr. Alzheimer Res. 8, 213-221.
149. Wolf A., Bauer B., and, Hartz A. M. S., (2012) ABC transporters and the Alzheimer's disease enigma. Front. Psychiartry 3, 1-14.
150. Wood W. G., Gorka C., and, Schroeder F., (1989) Acute and chronic effects of ethanol on transbilayer membrane domains. J. Neurochem. 52, 1925-1930. (Pubitemid 19140784)
151. + -ATPase activity, interdigitation, and increases fluidity of brain synaptic plasma membranes. Brain Res. 683, 36-42.
152. Wood W. G., Schroeder F., Igbavboa U., Avdulov N. A., and, Chochina S. V., (2002) Brain membrane cholesterol domains, aging, and amyloid beta-peptides. Neurobiol. Aging 23, 685-694. (Pubitemid 35217695)
153. Wood W. G., Eckert G. P., Igbavboa U., and, Müller W. E., (2003) Amyloid beta-peptide interactions with membranes and cholesterol: Causes or casualties of Alzheimer's disease. Biochim. Biophys. Acta 1610, 281-290. (Pubitemid 36324471)
154. Wood W. G., Igbavboa U., Eckert G. P., Johnson-Anuna L. N., and, Müller W. E., (2005) Is hypercholesterolemia a risk factor for Alzheimer's disease? Mol. Neurobiol. 31, 185-192. (Pubitemid 41271202)
155. Wood W. G., Igbavboa U., Eckert G. P., and, Müller W. E., (2007) Cholesterol-A janus-faced molecule in the central nervous system, in Handbook of Neurochemistry and Molecular Neurobiology-Neural Membranes and Transport, (Lajtha A., and, Reith M. E. A., eds), pp. 151-170. Springer, New York.
156. Wood W. G., Igbavboa U., Müller W. E., and, Eckert G. P., (2011) Cholesterol asymmetry in synaptic plasma membranes. J. Neurochem. 116, 684-689.
157. Yao Z. X., and, Papadopoulos V., (2002) Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity. FASEB J. 16, 1677-1679.
158. Yao J., Ho D., Calingasan N. Y., Pipalia N. H., Lin M. T., and, Beal M. F., (2012) Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. J. Exp. Med. 209, 2501-2513.
159. +)-ATPase ATP hydrolyzing activity in the human erythrocyte. Biochim. Biophys. Acta 727, 39-44. (Pubitemid 13186861)
160. Ying M., Grimmer S., Iversen T.-G., van Deurs B., and, Sandvig K., (2003) Cholesterol loading induces a block in the exit of VSVG from the TGN. Traffic 4, 772-784. (Pubitemid 37361857)
161. Zhang J., (2011) Epidemiological link between low cholesterol and suicidality: a puzzle never finished. Nutr. Neurosci. 14, 268-287.
162. Zhong N., and, Weisgraber K. H., (2009) Understanding the association of apolipoprotein E4 and Alzheimer disease: clues from its structure. J. Biol. Chem. 284, 6027-6031.